Bioventus Inc.BVS

Bioventus Inc. filed a small mountain of Form 4s on 4 June 2026, but the real document to read is its 10-Q for the quarter ended 28 March 2026. The headline is a $132.1 million revenue run-rate, up on the prior-year comparator but still short of the $150 million aspiration floated in 2021. Net income was a modest $3.1 million, EPS $0.04, and operating cash flow $8.9 million, while inventory climbed $2.6 million to $83.2 million. The company’s cash position is $35.8 million-enough to keep the lights on, not enough to light a buyback program that has become the centrepiece of its market narrative.

What Bioventus actually sells are orthobiologics and stimulators: knee gels (SUPARTZ FX, GELSYN-3, DUROLANE), bone-graft substitutes for surgical repair, and peripheral nerve stimulators pitched as non-drug, non-surgical pain relief. The product pages promise patient access and payer partnerships, but the balance sheet quietly records $83.2 million of inventory waiting for a code, a prescription, and an insurer willing to pay. The company’s payer page boasts a team of specialists ready to work with insurers, yet the 10-Q shows no acceleration in receivables collection; days sales outstanding remain unmentioned. The polished brochures is full of smiling clinicians and patients; the 10-Q is full of receivables and inventory.

Q1 2026 numbers are filed, dated, and specific. Revenue $132.1M, net income $3.1M, operating income $8.4M, diluted EPS $0.04, weighted diluted shares 70.0M. Cash and equivalents $35.8M, operating cash flow $8.9M, capex $574k, R&D $2.5M, inventory $83.2M. Liabilities $416.3M leave shareholders’ equity at $188.9M. The 8-K filed on 21 May 2026 confirms CMS updated billing rules for non-invasive bone stimulators under HCPCS codes E0747, E0748, and E0760, a policy change that should, in theory, help revenue recognition timing; in practice, the market did not reward the news. The company’s German bone-graft page showcases a “comprehensive portfolio” for surgeons, yet the US filings show no geographic segment breakout that would let investors size the contribution from non-US markets.

For context on the product set, see Bioventus’ official products page, which lists the stimulators, gels, and surgical substitutes; the German bone-graft page is here; the payer page is here. The CMS policy update is confirmed in the 8-K dated 21 May 2026. The SEC’s companyfacts JSON and submissions JSON round out the primary source set for those wanting to audit the filings line-by-line.

The tension is visible: the company’s market story runs ahead of its cash-generation story. The buyback optics are strong in the comms deck, the Form 4s are dutifully filed, and the surgical catalogues make for glossy slideware, but the 10-Q shows a company that is operationally stable rather than spectacular. Inventory is growing, receivables are unquantified in the public filings, and the cash balance is modest relative to the narrative’s ambitions. What remains unproven is how quickly the payer and coding changes will translate into faster cash collection and margin expansion. The evidence to deepen the file would be a segment breakout showing non-US contribution, a quantified days-sales-outstanding metric in the 10-Q, and a concrete update on the timing of CMS coding changes’ cash-flow impact. Until then, the story stays on the shelf with the inventory.